Jessica Schiavi
Family · Collingswood, NJNPI 1033676838
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,900, 5.2 times the $366 reported in 2021. Among family clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$726
- AbbVie$635
- AstraZeneca$541
- Johnson & Johnson$511
- Daiichi Sankyo Inc.$279
- Merck$259
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,853100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $726 |
| AbbVie | 33 | $635 |
| AstraZeneca | 27 | $541 |
| Johnson & Johnson | 5 | $511 |
| Daiichi Sankyo Inc. | 21 | $279 |
| Merck | 11 | $259 |
| Pfizer | 13 | $251 |
| Kowa Pharmaceuticals America, Inc. | 8 | $234 |
| Lilly USA, LLC | 8 | $151 |
| Otsuka America Pharmaceutical, Inc. | 8 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $132 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $96 |
| Almatica Pharma LLC | 6 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $89 |
| GSK | 6 | $83 |
| Exact Sciences | 3 | $80 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Astellas Pharma US Inc | 4 | $64 |
| Amgen | 4 | $60 |
| Tolmar, Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $36 |
| Novartis | 2 | $35 |
| Eisai Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Protega Pharmaceutials Inc | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,853 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 19 | $26,496 |
| VascepaIcosapent Ethyl | 17 | $11,420 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $7,932 |
| Olmesartan Medoxomil | 68 | $1,436 |
| Rosuvastatin Calcium | 73 | $1,330 |
| Fluticasone Propionate | 33 | $662 |
| Atorvastatin Calcium | 53 | $634 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $572 |
| Bupropion XlBupropion Hcl | 11 | $487 |
| Losartan Potassium | 49 | $455 |
| Alendronate Sodium | 25 | $424 |
| Escitalopram Oxalate | 42 | $424 |
| Ezetimibe | 14 | $400 |
| Amlodipine Besylate | 76 | $399 |
| Metoprolol Succinate | 16 | $292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $726 | $26,49619 claims |
| AstraZenecaBreztri Aerosphere | $541 | $7,93214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.
Other family in Collingswood
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
- Toni Michelle SeibertColumbus$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.